326 related articles for article (PubMed ID: 11880489)
1. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
2. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Schilling G; Coonfield ML; Ross CA; Borchelt DR
Neurosci Lett; 2001 Nov; 315(3):149-53. PubMed ID: 11716985
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
[TBL] [Abstract][Full Text] [Related]
4. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
[TBL] [Abstract][Full Text] [Related]
5. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Huntington Study Group
Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
[TBL] [Abstract][Full Text] [Related]
7. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
[TBL] [Abstract][Full Text] [Related]
8. Coenzyme Q10 as a possible treatment for neurodegenerative diseases.
Beal MF
Free Radic Res; 2002 Apr; 36(4):455-60. PubMed ID: 12069110
[TBL] [Abstract][Full Text] [Related]
9. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
[TBL] [Abstract][Full Text] [Related]
10. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
11. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Dedeoglu A; Kubilus JK; Yang L; Ferrante KL; Hersch SM; Beal MF; Ferrante RJ
J Neurochem; 2003 Jun; 85(6):1359-67. PubMed ID: 12787055
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
14. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
15. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
16. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
17. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.
Beal MF
Biofactors; 1999; 9(2-4):261-6. PubMed ID: 10416039
[TBL] [Abstract][Full Text] [Related]
18. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Huang HM; Dedeoglu A; Park L; Ferrante KL; Kwon J; Borchelt DR; Ross CA; Gibson GE; Beal MF
Ann Neurol; 2001 Jul; 50(1):112-7. PubMed ID: 11456300
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Ferrante RJ; Andreassen OA; Jenkins BG; Dedeoglu A; Kuemmerle S; Kubilus JK; Kaddurah-Daouk R; Hersch SM; Beal MF
J Neurosci; 2000 Jun; 20(12):4389-97. PubMed ID: 10844007
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction.
Mehan S; Monga V; Rani M; Dudi R; Ghimire K
Indian J Pharmacol; 2018; 50(6):309-319. PubMed ID: 30783323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
